Damora Therapeutics Appoints Industry Veteran Jennifer Jarrett as President and CEO; Adds Two Accomplished Biotech Leaders to Board of Directors

Key Highlights

• Jennifer Jarrett appointed as President and Chief Executive Officer (CEO), effective March 30, 2026. She will also join the Board of Directors.
• Appointment of two prominent industry leaders—Dr. Cameron Turtle and Mike Landsittel—to the Board of Directors.
• Peter Harwin named Chairman of the Board of Directors.
• Damora Therapeutics advancing towards clinical development of lead program DMR-001 and additional pipeline assets in 2026.

Detailed Report

BOSTON, March 23, 2026 – Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company focused on transforming care for patients with blood disorders, made several major leadership announcements that could have significant strategic and operational implications for the company and its shareholders.

Appointment of Jennifer Jarrett as President and CEO

The Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett brings nearly 30 years of executive experience spanning biotechnology, technology, and finance. She is recognized for her successful track record in oncology drug development, organizational leadership, and building high-growth companies.

• Background: Most recently, Ms. Jarrett served as Chief Operating Officer of Arcus Biosciences, where she also held the positions of Chief Financial Officer and Board Director. She played pivotal roles at Uber Technologies as Vice President of Corporate Development and Capital Markets, and at Medivation as CFO, helping drive the company’s development of XTANDI® (enzalutamide) and its subsequent acquisition by Pfizer.
• Investment Banking Experience: Ms. Jarrett spent two decades in investment banking, notably leading Citigroup’s west coast life sciences group, with prior roles at Credit Suisse and Donaldson, Lufkin & Jenrette.
• Education and Board Roles: Ms. Jarrett holds a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University. She currently serves on the boards of Sagimet Biosciences, Syndax Pharmaceuticals, and Zura Bio.

Strategic Significance for Investors

The appointment of Ms. Jarrett is a potential inflection point for Damora Therapeutics. Her leadership is expected to accelerate the company’s efforts to bring innovative medicines to patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs). With a strong balance sheet and a portfolio of potential best-in-class therapies, Damora is positioned for rapid advancement of its lead program DMR-001 and the expansion of its pipeline, both of which could have material impacts on the company’s future growth and valuation.

Board of Directors Enhancements

• Dr. Cameron Turtle joins the Board. He is currently CEO of Spyre Therapeutics and has a strong background as a Venture Partner at Foresite Labs, Chief Strategy Officer at BridgeBio Pharma, and Chief Business Officer at Eidos Therapeutics. Dr. Turtle holds a B.S. in bioengineering from the University of Washington and a D.Phil. in cardiovascular medicine from Oxford University, where he was a Rhodes Scholar.
• Mike Landsittel is also joining the Board. He brings significant biotech finance and operations expertise, most notably serving as Chief Financial Officer of Blueprint Medicines during its acquisition by Sanofi. He was instrumental in raising approximately \$4 billion in capital and leading the company’s commercial launch of AYVAKIT® (avapritinib). Mr. Landsittel holds a B.B.A. from the University of Michigan and an M.B.A. from Dartmouth College’s Tuck School.
• Peter Harwin, Founding Partner at Fairmount Funds Management, has been named Chairman of the Board.
• The company also announced the departure of Dr. Carl Goldfischer, Dr. Jayson Dallas, and Amit Munshi from the Board, recognizing their contributions, particularly regarding the recent Damora-Galecto transaction.

Company Outlook and Pipeline

Damora Therapeutics is advancing a new class of biologics targeting mutCALR-driven MPNs, including essential thrombocythemia and myelofibrosis—diseases with significant unmet medical need. The company aims to enter clinical development for multiple programs in 2026, targeting broad mutation coverage and enhanced patient convenience, which could dramatically improve patient outcomes and position Damora as a leader in this therapeutic space.

Potential Impact on Shareholders and Share Price

• Leadership Upgrades: The addition of high-profile executives and directors with deep industry, financial, and operational expertise could be seen as a strong signal of company momentum and value creation potential.
• Pipeline Advancement: Confirmation of a strong balance sheet and readiness to enter clinical development with multiple best-in-class programs in 2026 represents a material catalyst that could drive significant re-rating of Damora’s valuation.
• Strategic Direction: The company’s stated intent to develop therapies with broad mutation coverage and exceptional convenience addresses pressing unmet needs, which, if successful, could have profound market and financial implications.
• Recent M&A Activity: Reference to the Damora-Galecto transaction and recent board exits suggests ongoing strategic activity, which may be of interest to investors seeking catalysts or considering M&A premium expectations.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company focused on redefining care for patients with hematologic disorders. The company is developing novel biologics for mutCALR-driven myeloproliferative neoplasms, aiming to rapidly advance these programs into clinical development and address significant unmet needs in essential thrombocythemia and myelofibrosis.

For more information, investors can visit www.damoratx.com or follow the company on LinkedIn.

Contact Information

Media Contact: Lia Dangelico, Deerfield Group, [email protected]
Investor Contact: Brian Ritchie, LifeSci Advisors, [email protected]

Disclaimer: This article contains forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those projected. Shareholders and potential investors are advised to review the company’s filings with the SEC for risk factors and exercise caution when interpreting forward-looking statements. This article is for informational purposes only and does not constitute investment advice.

View Damora Therapeutics, Inc. Historical chart here